Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions. Reporting in Nature Cancer, the researchers showed for the first time in human cells and a mouse model that inhibiting the c-Rel molecule in myeloid cells — as opposed to lymphoid cells that today’s immunotherapies target — blocked the production of immune suppressor cells and significantly shrank tumors.
- Predicts the onset of Alzheimer’s Disease (AD) using deep learning-based Splice-AI
- When foams collapse (and when they don’t)
- Oahu marine protected areas offer limited protection of coral reef herbivorous fishes
- Picture books can boost physical activity for youth with autism
- Atherosclerosis can accelerate the development of clonal hematopoiesis, study finds